5-2010

Significant Interactions with the Most Commonly Used Herbal and Nonherbal Supplements Impact Warfarin Safety and Efficacy

Brittany Jean Sagers
Utah State University

Follow this and additional works at: https://digitalcommons.usu.edu/honors

Part of the Dietetics and Clinical Nutrition Commons

Recommended Citation
https://digitalcommons.usu.edu/honors/58

This Thesis is brought to you for free and open access by the Honors Program at DigitalCommons@USU. It has been accepted for inclusion in Undergraduate Honors Capstone Projects by an authorized administrator of DigitalCommons@USU. For more information, please contact rebecca.nelson@usu.edu.
SIGNIFICANT INTERACTIONS WITH THE MOST COMMONLY USED HERBAL AND NONHERBAL SUPPLEMENTS IMPACT WARFARIN SAFETY AND EFFICACY

by

Brittany Jean Sagers

Thesis submitted in partial fulfillment of the requirements for the degree of

DEPARTMENTAL HONORS in

Dietetics in the Department of Nutrition, Dietetics and Food Sciences

Approved:

Thesis/Project Advisor
Megan Bunch, RD, MS

Departmental Honors Advisor
Megan Bunch, RD, MS

Director of Honors Program
Dr. Christie Fox

UTAH STATE UNIVERSITY
Logan, UT

Spring 2010
# Table of Contents

Abstract..............................................................................................................................................4  
List of Figures.........................................................................................................................................5  

Review of Literature  
Warfarin................................................................................................................................................6  
Atrial Fibrillation..................................................................................................................................6  
Use of HDS in the US ..............................................................................................................................7  
Use of VKAs..........................................................................................................................................8  
Mechanism of Warfarin..........................................................................................................................8  
Factors Influencing Warfarin’s Effects .....................................................................................................9  
Dietary Interactions with Warfarin........................................................................................................10  
Medicinal Interactions with Warfarin ......................................................................................................11  
Herbal and Nonherbal Dietary Supplement Interactions with Warfarin.............................................11  
Fish Oil and Flaxseed Oil.......................................................................................................................12  
Ginseng...............................................................................................................................................12  
Glucosamine.......................................................................................................................................13  
Echinacea...........................................................................................................................................13  
Garlic....................................................................................................................................................13  
Ginkgo..................................................................................................................................................14  
St. John’s wort ....................................................................................................................................14  
Conclusion...........................................................................................................................................15  
References..........................................................................................................................................16  

Manuscript..........................................................................................................................................18  
Introduction.........................................................................................................................................19  
Methods.............................................................................................................................................20  
Results...............................................................................................................................................21  
Discussion..........................................................................................................................................21
Abstract

**Background:**
Nearly 20% of adult Americans used herbal therapies in 2007, but greater than two-thirds failed to report such use to their medical provider. Significant patient harm may occur when herbal supplements are taken in conjunction with warfarin; however, patients and medical providers may not be aware of these interactions and this may place patients at risk for life-threatening bleeds or thrombotic complications.

**Methods:**
The authors determined the top 25 herbal and 25 nonherbal supplements used by Americans using sales data from 2008, and each product was reviewed for its potential to interact with warfarin. Electronic searches were conducted using the Natural Medicines Comprehensive Database, AltMedDex (Micromedex) and Natural Standards databases. Search terms included common herbal names, warfarin, and anticoagulants. Databases were reviewed for herb-drug interactions with warfarin. Supplements with a purported theoretical interaction only were excluded from the analysis.

**Results:**
Of the most commonly used herbal and nonherbal supplements used, more than half demonstrate a clinically significant drug interaction with warfarin therapy. Specifically, 8 of 13 were found to potentiate a bleeding risk, and 5 of 13 were found to decrease the effectiveness of warfarin. Documented bleeding events have been linked to the use of some of these products (e.g. cranberry, garlic, ginkgo, and saw palmetto); whereas others have been found to demonstrate a clinically significant increase (e.g. glucosamine / chondroitin, essential fatty acids, multi-herb products, evening primrose oil) or decrease (e.g. coenzyme Q10, soy, melatonin, ginseng, St. John’s wort) in prothrombin time and required warfarin dose adjustments or vitamin K administration.

**Conclusions:**
Of the most commonly used herbal and nonherbal supplements, the majority impacted prothrombin times and 26% significantly impacted warfarin therapy safety or efficacy. The combined use of herbal-warfarin products has the potential to result in significant bleeding or thrombotic sequelae complicating the management of an already high-risk medication. Medical providers must be proactive in asking about supplement use and then discussing the risks of herbal-warfarin interactions with their patients.
List of Figures

Figure 1 ...................................................................................................................... 7
Figure 2 ...................................................................................................................... 9
Review of Literature

Warfarin

Warfarin sodium, commonly known under the brand name Coumadin, is a popular anticoagulant drug. It is the most widely prescribed oral anticoagulant in North America and has been proven effective in the prevention of thromboembolic events in patients with chronic atrial fibrillation, prosthetic heart valves, venous thromboembolism, and coronary artery disease (1). Coumarins or vitamin K antagonists (VKAs) have been the foundation of oral anticoagulant therapy for more than 50 years (2).

Atrial Fibrillation

Atrial fibrillation (AF) is a cardiac arrhythmia affecting an estimated in 2.2 million people in America and 4.5 million in the European Union (3). In some cases, AF can cause chest pain or heart failure, especially when the heart rhythm is very rapid (4). Frequently, people who have AF are asymptomatic. However, even if asymptomatic, AF can increase the risk of stroke (4). About 15 percent of patients with AF have experienced a stroke (5).

Clinical risk factors for AF include advanced age, diabetes, hypertension, congestive heart failure, rheumatic and nonrheumatic valve disease, and myocardial infarction (6). Three to five percent of people older than 65 years have atrial fibrillation (5). To reduce stroke risk in patients with AF, anticoagulant and antiplatelet medications are used to thin the blood reducing risk for emboli (5). Warfarin is the anticoagulant most frequently used for this purpose, and aspirin is the antiplatelet drug most often used (5). Long-term use of warfarin in patients with AF and other stroke risk factors can reduce stroke by 68 percent (5).
Use of HDS in the US

In 1994, the Dietary Supplement Health & Education Act (DSHEA) was passed that defines a supplement as: a product other than tobacco, is intended to supplement the diet, contains one or more dietary ingredients, intended to be taken by mouth, and labeled as being a dietary supplement (7). In 2004, dietary supplement sales exceeded $20 billion (8). According to the National Center for Complementary and Alternative Medicine (NCCAM), “a national survey conducted in 2007 found that 17.7 percent of American adults had used "natural products" (i.e., dietary supplements other than vitamins and minerals) in the past 12 months (9). The most popular products used by adults for health reasons in the past 30 days were fish oil/omega 3/DHA (37.4%), glucosamine (19.9%), echinacea (19.8%), flaxseed oil or pills (15.9%), and ginseng (14.1%)” as seen in figure 1 (10).

Table 3. Frequencies and age-adjusted percentages of adults 18 years and over who used selected types of nonvitamin, nonmineral, natural products for health reasons in the past 30 days, by type of product used: United States, 2007

<table>
<thead>
<tr>
<th>Nonvitamin, nonmineral, natural products</th>
<th>Used selected nonvitamin, nonmineral, natural products¹</th>
<th>Number in thousands</th>
<th>Percent² (standard error)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fish oil or omega 3 or DHA</td>
<td>10,923</td>
<td>37.4 (1.13)</td>
<td></td>
</tr>
<tr>
<td>Glucosamine</td>
<td>6,132</td>
<td>19.9 (0.91)</td>
<td></td>
</tr>
<tr>
<td>Echinacea</td>
<td>4,846</td>
<td>15.9 (1.07)</td>
<td></td>
</tr>
<tr>
<td>Flaxseed oil or pills</td>
<td>4,416</td>
<td>14.1 (0.83)</td>
<td></td>
</tr>
<tr>
<td>Ginseng</td>
<td>3,346</td>
<td>13.0 (0.53)</td>
<td></td>
</tr>
<tr>
<td>Combination HMO pill</td>
<td>3,446</td>
<td>11.3 (0.56)</td>
<td></td>
</tr>
<tr>
<td>Ginkgo biloba</td>
<td>2,977</td>
<td>11.2 (0.52)</td>
<td></td>
</tr>
<tr>
<td>Chondroitin</td>
<td>3,950</td>
<td>11.0 (0.65)</td>
<td></td>
</tr>
<tr>
<td>Garlic supplements</td>
<td>3,276</td>
<td>8.7 (0.50)</td>
<td></td>
</tr>
<tr>
<td>Coenzyme Q-10</td>
<td>2,601</td>
<td>6.9 (0.41)</td>
<td></td>
</tr>
<tr>
<td>Fiber or psyllium</td>
<td>1,791</td>
<td>6.7 (0.41)</td>
<td></td>
</tr>
<tr>
<td>Green tea pills</td>
<td>1,528</td>
<td>6.0 (0.63)</td>
<td></td>
</tr>
<tr>
<td>Cranberry gels, gelcaps</td>
<td>1,580</td>
<td>5.1 (0.48)</td>
<td></td>
</tr>
<tr>
<td>Saw palmetto</td>
<td>1,482</td>
<td>5.0 (0.55)</td>
<td></td>
</tr>
<tr>
<td>Soy supplements or isoflavonides</td>
<td>1,383</td>
<td>4.8 (0.48)</td>
<td></td>
</tr>
<tr>
<td>Melatonin</td>
<td>1,206</td>
<td>4.3 (0.43)</td>
<td></td>
</tr>
<tr>
<td>Grape seed extract</td>
<td>1,214</td>
<td>4.1 (0.37)</td>
<td></td>
</tr>
<tr>
<td>MSM (methylsulfonylmethane)</td>
<td>1,312</td>
<td>3.7 (0.49)</td>
<td></td>
</tr>
<tr>
<td>Milk thistle</td>
<td>1,001</td>
<td>3.4 (0.39)</td>
<td></td>
</tr>
</tbody>
</table>

¹Respondents may have used more than one nonvitamin, nonmineral, natural product.
²The denominator used in the calculation of percentages was the number of adults who used nonvitamin, nonmineral, natural products within the past 30 days, excluding persons with unknown information for usage of the specified nonvitamin, nonmineral, natural product.

**NOTE:** Estimates were age-adjusted using the projected 2000 U.S. population as the standard population and using four age groups: 18–24 years, 25–44 years, 45–64 years, and 65 years and over.

**DATA SOURCE:** CDC/NCHS, National Health Interview Survey, 2007. Estimates are based on household interviews of a sample of the civilian, noninstitutionalized population.

Figure 1: Frequencies and age-adjusted percentages of adults ≥ 18 yrs old who used nonvitamin, nonmineral, natural products for health reasons in the past 30 days.
**Use of VKAs**

In clinical practice, the use of VKAs is complicated. First, they have a limited therapeutic window. Second, they exhibit substantial variability in dose response among subjects. Third, they are susceptible to interactions with drugs and diet. Fourth, they have laboratory control that can be difficult to standardize. Lastly, there are difficulties in dosing as a consequence of patient nonadherence and miscommunication between the physician and patient (2). Warfarin use is somewhat restricted by a justifiable fear of bleeding as well as drug and food interactions that are frequently cited as causes of adverse events with warfarin. Noting this challenging situation in the utilization of warfarin, safety must be carefully practiced while taking it.

**Mechanism of Warfarin**

The effects of warfarin occur due to interference with the cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K epoxide). Vitamin K is a cofactor for the carboxylation of glutamate residues to \( \gamma \)-carboxyglutamates (Gla) on the N-terminal regions of vitamin K-dependent proteins (11). These proteins include coagulation factors II, VII, IX, and X, and require vitamin K for \( \gamma \)-carboxylation for biological activity. By inhibiting the vitamin K conversion cycle, warfarin stimulates hepatic production of partially decarboxylated proteins with decreased coagulant activity (11).

Carboxylation supports binding of the vitamin K-dependent coagulation factors to phospholipid surfaces, thus increasing blood coagulation (11). In order for \( \gamma \)-carboxylation to work effectively, the reduced form of vitamin K (vitamin KH\(_2\)) is required. Coumarins block the formation of vitamin KH\(_2\) by inhibiting the enzyme vitamin K epoxide reductase, thereby restricting the \( \gamma \)-carboxylation of the vitamin K-dependent coagulant proteins (11). The vitamin
K antagonists also inhibit carboxylation of the regulatory anticoagulant proteins C and S. Low doses of vitamin K\textsubscript{1} (phytonadione) are capable of aiding in overcoming the anticoagulant effect of coumarins because vitamin K\textsubscript{1} bypasses vitamin K epoxide reductase (11). Subjects treated with large doses of vitamin K\textsubscript{1} (usually greater than five mg) can be unaffected by warfarin for up to a week because vitamin K\textsubscript{1} accumulating in the liver is available to bypass vitamin K epoxide reductase (11). Figure 2 depicts warfarin interaction in the vitamin K cycle (12).

**Figure 2: Warfarin Interaction in the Vitamin K Cycle**

**Factors Influencing Warfarin’s Effects**

The anticoagulant response to warfarin is affected by pharmacokinetic factors, including drug and herbal/nonherbal supplement interactions that affect its absorption or metabolic clearance, genetic factors such as hereditary resistance to warfarin, and food interactions such as dietary vitamin K intake (11). Warfarin requires monitoring and frequent dose adjustment to maintain the desired therapeutic action and minimize adverse bleeding events. A thrombosis is a result of underanticoagulation, which can be fatal. A hemorrhage is a result of over-anticoagulation, which can also be life-threatening. Length of treatment varies, from 6 weeks to
6 months for venous thrombosis, to life-long treatment for cardiac indications or repeated thrombosis (13).

Patients taking oral anticoagulant drugs, such as warfarin, must regulate their international normalized ratio (INR) measured routinely with appropriate anticoagulant dose adjustment. Some patients are particularly sensitive to oral anticoagulants and, in such individuals, small increases in dose, or introduction or discontinuation of interacting medicines, herbal preparations and certain foods can cause significant changes in the anticoagulant effect (13). Polypharmacy is not uncommon, which complicates the efficacy of warfarin. Patients taking warfarin should be aware of the risks of taking other prescribed or purchased medicines, herbal products and specific foods without first discussing it with their physician.

**Dietary Interactions with Warfarin**

As previously stated, warfarin use is subject to dangerous interactions with other medications as well as some food products. Due to the actions of warfarin interfering with the vitamin K conversion cycle, dietary vitamin K intake must remain consistent on a daily basis to reduce the risk of hemorrhage or thrombosis. Persons on long-term warfarin therapy are vulnerable to fluctuating levels of dietary vitamin K, which is obtained predominantly from phylloquinones found in plant foods (11).

Phylloquinones inhibit the anticoagulant effect of warfarin because they are reduced to vitamin KH₂ through the warfarin-insensitive pathway (11). Significant fluctuations in vitamin K intake occur in both healthy and sick individuals. Increased intake of dietary vitamin K sufficient to lessen the anticoagulant effect of warfarin occurs in patients consuming green vegetables or vitamin K-containing supplements while following weight-reduction diets as well as in patients supplementing with intravenous vitamin K (11). Reduced dietary vitamin K intake has the
potential to affect warfarin efficacy in sick patients treated with antibiotics and intravenous fluids without vitamin K supplementation and in circumstances of fat malabsorption (11).

**Medicinal Interactions with Warfarin**

Warfarin also interacts with some common drugs such as aspirin, nonsteroidal antiinflammatory drugs (NSAIDs), and penicillins in high doses (11). These drugs inhibit platelet function and thus increase the risk of warfarin-associated bleeding. Of these, aspirin is the most critical because of its universal use and drawn out effect. Aspirin and nonsteroidal antiinflammatory drugs can also increase the risk of upper gastrointestinal bleeding as a result of them producing gastric erosions (11). The risk of clinically significant bleeding is amplified when elevated amounts of aspirin are taken throughout high-intensity warfarin therapy (11).

**Herbal and Nonherbal Dietary Supplement Interactions with Warfarin**

Warfarin has been documented to interact with herbal and nonherbal dietary supplements (HDS) (11). However, little is known about the great extent to which some of the most commonly used HDS may impact warfarin safety and efficacy. Although herbal remedies are perceived as being natural and therefore safe, many have adverse effects that can sometimes produce life-threatening consequences.

It is important to determine the degree to which HDS can interfere with warfarin because of the rapidly growing dietary supplement market and consumer demand in the United States. According to the research completed through this thesis, the top five products in Figure 1 (fish oil, flaxseed oil, glucosamine, echinacea, and ginseng) were shown to have an interaction with warfarin. Also, as documented in the manuscript portion of this thesis, garlic (37-45), ginkgo (49, 52-56) and St. John’s wort (80-84) should be avoided while taking warfarin. Because of the
high risk of adverse effects while concurrently taking these common HDS and warfarin, a brief review of each HDS will follow.

**Fish Oil and Flaxseed Oil**

Fish oil and flaxseed oil both had minor interactions, mainly with platelets (35-36). Many people consume fish and flax seed oils because of the purported health benefits of the omega-3 fatty acids they contain. Omega-3 fatty acids have been thought to reduce the risk for cardiovascular disease and some cancers, as well as improve brain health. Some research has shown that the omega-3 component of fish oils may suppress thromboxane A2 synthesis. This may intensify the effects of warfarin, thus increasing the chances of bleeding. Conflicting research has suggested that fish oil does not have an additive effect with aspirin. Data does suggest that 3-6g/day does not affect INR (35-36).

**Ginseng**

The source of the ginseng root and its method of extraction can result in a wide array of ginseng products. Ginseng is touted as an immune system stimulant that increases vigor, sexual potency, and longevity, and for use as an antidiabetes agent (14). It is also used as medicine in Chinese culture for congestive heart failure (CHF), myocardial infarction, and angina pectoris (14). Ginseng use should be avoided while taking warfarin (76-78). Ginseng may inhibit platelet aggregation consequently decreasing the effects of warfarin. A recent study inspecting the effect of 3 weeks of American ginseng on the effect of warfarin in healthy volunteers found a statistically significant but quantitatively small decrease in INR of 0.19, as well as a decrease in warfarin plasma area under the curve (AUC) (15). These results imply that this specific ginseng preparation may produce a minor reduction in the efficacy of warfarin, perhaps by way of accelerated clearance.
**Glucosamine**

Glucosamine is recommended to be used with caution while taking warfarin although the exact mechanism of the interaction is unknown (2-4). Glucosamine is a chemical component of heparin, a widely used injectable anticoagulant (16). It is possible that the combining of warfarin with higher-dose glucosamine and chondroitin might have had an additive pharmacodynamic effect on coagulation (16). At the usual dosages of glucosamine (1500 mg) and chondroitin (1200 mg) used on a daily basis, these supplements alone or in combination do not appear to cause a clinically significant interaction with warfarin (16). Nevertheless, it is advised to monitor for INR changes in patients taking warfarin and beginning a supplement or drug that has not been thoroughly investigated for its effect on warfarin.

**Echinacea**

Echinacea is commonly thought to stimulate the immune system and therefore prevent infections. It has been shown to have minor interactions with warfarin. Flavonoids from echinacea may inhibit or induce cytochrome P450 enzymes, depending on their structure and assay conditions (14). A minor impact of CYP function was established through in vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: citrus aurantium, echinacea purpurea, milk thistle, and saw palmetto.

**Garlic**

Garlic is often used by patients for remedy of infectious conditions because of its presumed antimicrobial and immune-boosting activity. Garlic has been considered to have cholesterol-lowering and other antiatherosclerotic and antihypertensive properties and is used in the prevention of cardiovascular disease (14). It has been shown to increase fibrinolytic activity,
and may inhibit platelet aggregation by reducing thromboxane B2 thereby, increasing risk for bleeding.

Garlic’s active component, ajoene inhibits collagen-induced platelet aggregation; thus, patients with cardiovascular disease often use garlic for its antiplatelet and fibrinolytic effects (14). Nevertheless, the risk of bleeding in patients using warfarin increases, so its concomitant use should be avoided. It is worthy to note that not all garlic products contain the constituents that possess “antiplatelet properties”. It has been advised that garlic supplements be discontinued ten days prior to surgery to prevent excessive bleeding. Ingestion of normal amounts of dietary garlic should not affect bleeding times (37-45).

**Ginkgo**

Ginkgo is a popular HDS and is one of the bestselling herbal remedies in the United States for cognitive impairment (14). Ginkgo biloba beginnings date back centuries to the Permian period, making it one of the world’s oldest living tree species (14). The main implications for ginkgo use are peripheral vascular disease such as intermittent claudication and, more chiefly, "cerebral insufficiency" (17). It has been documented to increase the risk of bleeding while taking warfarin. This is thought probable by inhibition of cytochrome P450 2C9 by ginkgo. Also, ginkgo is thought to displace platelet activating factor (PAF), inhibiting PAF-induced platelet aggregation.

**St. John’s Wort**

St. John’s wort is frequently used to treat depression, anxiety, sleep disorders, the common cold, herpes, and the human immunodeficiency virus (HIV) (14). It acts as a hepatic cytochrome P450 enzyme inducer (CYP2C9, CYP1A, CYP3A4). Simultaneous use of St. John’s wort with warfarin reduces prothrombin time, which may produce subtherapeutic
anticoagulation and increase the risk of thromboembolism (14). Patients with a history of stroke, thrombosis, atrial fibrillation, or prosthetic cardiac valves should avoid the use of St. John’s wort while taking warfarin (14).

**Conclusion**

From this evidence alone, there are major risks when using HDS and warfarin concomitantly. Steps must be taken to bridge the communication gap that exists between physicians and patients with regard to supplement use. To ensure that patients are taking warfarin safely, physicians must be aware of the risks HDS pose with concomitant use of warfarin. Physicians must be proactive in asking their patients about such use and discussing the risks involved to aid in preventing serious complications with an already high risk medication.
References


Manuscript

Significant interactions with the most commonly used herbal and nonherbal supplements impact warfarin safety and efficacy

Jennifer Strohecker¹, Megan B. Smith², Nedra Christensen², Brittany Sagers², John D. Day³, J. Peter Weiss³, Brian G. Crandall³, Jeffrey S. Osborn³, Jeffrey L. Anderson³, Brent Muhlestein³, Donald L. Lappe³, T. Jared Bunch²,³

¹ Intermountain Medical Center, Murray, Utah
² Department of Nutrition and Food Sciences, Utah State University, Logan, Utah
³ Department of Cardiology, Intermountain Medical Center, Murray, Utah

Address for correspondence: T. Jared Bunch, M.D.

Intermountain Heart Rhythm Specialists,
Intermountain Medical Center
Eccles Outpatient Care Center
5169 Cottonwood St, Suite 510
Murray, Utah, 84107
Fax: 801-507-3584
E-mail: Thomas.bunch@imail.org
Introduction:

For centuries, botanicals and their derivatives have been utilized for prevention and treatment of disease. Indeed, even today, due to extensive availability and widespread acceptance, herbal and dietary supplement (HDS) use has become commonplace. One out of five American’s reports using at least one HDS in the last twelve months, a trend that has continued to gain momentum over the last decade (1). Growing concern for patient safety has driven international and national groups in efforts towards regulation of the herbal supplement industry, but with limited success. In the present day era of patient guided research, selection and self-treatment with supplements, it is imperative that medical providers be proactive in inquiry about HDS use and provide relevant guidance in efforts to minimize potential adverse events. When combined with prescription drugs, herbal-drug interactions are of great concern because they may lead to unexpected, serious patient harm.

The supplement industry is the fastest growing share of the US pharmaceutical industry, with annual earnings approaching 24 billion dollars in 2007 (2). Today, greater than 1500 products claiming “functional support” of the bodies various organ systems line the shelves of pharmacies and health food stores, easily accessible to an often uneducated consumer. Ironically, HDS are not considered “drugs” by the Food and Drug Administration (FDA), and are therefore free from the safety and regulatory standards set in place by the FDA for other over the counter and prescription products. In 1994, the Dietary Supplement Health and Education Act (DSHEA) was passed and outlines the US regulations set in place for herbal and nonherbal supplements: the manufacturer is to ensure that the product is safe and labeling must include product ingredients (3). As a food source the preparation, packing, and holding of HDS are governed by the FDA’s ‘Good Manufacturing Practices’ (4). In June of 2007, the FDA
established regulations to require current “Good Manufacturing Practices” for dietary supplements that require dietary supplement manufacturers to evaluate the identity, purity, strength, and composition of their dietary supplements (5). Although these measures may help, the quandary with HDS continues to be, that the pharmacologic effects of these products are undefined, unpredictable, and potentially unsafe, yet the well-intended consumer has little knowledge of this. This can present the greatest risk to patients with multiple medical comorbidities, fragile end organ function, and those on complicated drug regimens. In 2002, the World Health Organization launched a global strategy with end goals of promoting consumer safety through industry regulation and standardization (6). Clearly, the unregulated use of HDS is not just a national, but an international concern.

The introduction of warfarin sodium in 1954 revolutionized the prophylaxis and treatment of thromboembolic disorders, and remains the gold standard oral anticoagulant. More than 22 million prescriptions for warfarin were filled in 2008, and enormous health care resources are dedicated to its management. In spite of efforts to achieve tight control of the international normalized ratio (INR), warfarin accounts for more emergency room visits than any other drug excluding insulin. In 2009, the Joint Commission of Healthcare Accreditation made the appropriate use of warfarin a National Patient Safety Goal (7). As part of this effort, it is crucial to understand the influence that HDS use may have on INR variability when taken concomitantly with warfarin. Such an understanding must be constantly reappraised as the kinds of HDS used varies as well as their relative frequency and quantify of use.

**Methods:**

The authors determined the top 20 herbal and 20 nonherbal supplements used by Americans using sales data from 2008 and each product was reviewed for its potential to interact
with warfarin (8). Electronic searches were conducted using the Natural Medicines Comprehensive Database, AltMedDex (Micromedex) and Natural Standard databases. Search terms included common herbal names, warfarin, and anticoagulants, and drug-drug interactions. Databases were reviewed for herb-drug interactions with warfarin. Databases were searched for relevant case reports and any clinical trials which documented an herbal/supplement – drug interaction with reported changes in INR, bleed risks, or thromboembolic events. Collected data was limited to English only reports and those with a documented human interaction. Supplements with a purported theoretical interaction only were excluded from the analysis.

Results:

Of the 40 most commonly used herbal and nonherbal supplements, more than half demonstrate an indirect or direct drug interaction with warfarin therapy. Of the top 10 most commonly used supplements, 80% have been reported to interact with warfarin therapy. Overall, 14 of 40 were associated with a clinically significant change in INR. Specifically, 9 of 14 were found to potentiate a bleeding risk, and 5 of 14 were found to decrease the effectiveness of warfarin. Documented bleeding events have been linked to the use of some of these products (e.g. cranberry, garlic, ginkgo, and saw palmetto); whereas others have been found to demonstrate a clinically significant increase (e.g. glucosamine / chondroitin, essential fatty acids, multi-herb products, evening primrose oil) or decrease (e.g. coenzyme Q10, soy, melatonin, ginseng, St. Johns’s wort) in prothrombin time thus necessitate warfarin dose adjustments or vitamin K administration.

Discussion:

The HDS industry has experienced enormous growth with extensive consumer acceptance and trust. A survey of 100 patients with CV disease on warfarin showed that many patients do
not view HDS as drugs, and most do not consult with their pharmacist/physician before taking a HDS (9). More than 2/3 of patients who use HDS fail to communicate use to their physicians/pharmacists, and physicians often fail to ask patients about HDS consumption as well (5, 9). The reasons for the communication gap are many: patients believe that health care professionals lack knowledge of or acceptance for HDS, patients perceive HDS as "natural" and do not relate their use to drug interaction (9), and medical providers may fail to ask about HDS use due to a lack of knowledge, confidence, or comfort with the subject matter (10). Addressing these issues will be paramount as clinicians seek to bridge this gap in order to improve safety outcomes, particularly in high-risk patient groups.

A survey of the literature shows that anticoagulant/antiplatelet therapies are among the drug classes most likely to interact with HDS (11). Of the 40 most commonly used HDS, more than half demonstrated a clinically significant change in INR values, and the majority were associated with a bleeding event or thromboembolic complication. While most of these reports are cited as individual case reports, the true level (degree/risk) of harm for warfarin-treated patients may actually be greater than is documented. Pharmacokinetic properties and toxicity parameters of individual herbs are not well studied, and drug-drug, drug-disease interactions are largely unknown. Additionally, a vast number of supplements are not marketed as “single-entity” products, but rather a potpourri of dozens or hundreds of individual ingredients. The new FDA regulation should impact quality of supplements. Unfortunately, companies have to be compliant to the new regulation by supplement June 2008, 2009, or 2010, depending on the number of personnel employed at the company. This will continue to impact the consistency of HDS in the marketplace. Without prior study it is completely unclear if the enhanced quality
which may provide relatively higher or lower HDS concentrations with favorability or unfavorability impact the many drug-HDS interactions.

Development, implementation, and adherence to a comprehensive management program that outlines standards of care have been shown to improve safety outcomes in anticoagulated patients. As such, inquiry and recommendation about herbal supplement use is an essential part of such a program. Important aspects to incorporate may be the following: proactive inquiry about herbal or supplement use separately from prescription or over the counter drug use; documentation of use in the medical record; active education of known risks/interactions between the specified herbal product and warfarin; and more frequent INR monitoring if necessary. Other valuable education points for patients who use HDS may be: encourage dialogue before use with physician/pharmacist; take the product consistently to achieve a more predictable effect on INR; to purchase the same brand of product to minimize constituent variability; follow up with routine testing as instructed; bring the HDS with them to all scheduled appointments; report any adverse events to their medical provider immediately. Additionally, encourage selection of supplements that are verified by the United States Pharmacopeia (USP).

Likewise, physicians and other medical providers must acknowledge a “communication gap” exists with their patients and make efforts to minimize this barrier. Self-education is critical, so that a knowledgeable exchange about the supplement industry, including DHSEA and rationale for safety risks, can be undertaken with patients. Physicians must recognize that HDS use is common and underreported, and therefore must be proactive and specific in patient interview. It is essential to be forthright with regard to the risks/benefits of using supplements, so that the patient can make an informed and educated decision. Likewise, it is imperative that
the physician be familiar with on-line herbal databases, such as AltMedDex (Micromedex), and utilizes them to search for herbal information, such as herbal-warfarin interactions.

Steps must be taken to bridge the communication gap that exists between physicians and patients with regard to supplement use. While warfarin remains the gold standard anticoagulant drug therapy for long-term management of patients at risk for thromboembolism, its safe use can be compromised by many factors, including HDS consumption. Our data shows that of the most commonly used HDS, warfarin-related drug interactions are very common and have been associated with bleeding. This risk is greatest in the 10 most commonly used herbal supplements, where 8 of 10 have demonstrated an HDS-warfarin interaction. Our research highlights/emphasizes the widespread risk that warfarin-treated patients are exposed to when self-medicating with HDS. It is imperative that action be taken to address communication-related barriers with regard to HDS use, and should include the steps outlined above. As hospitals seek to achieve compliance with the Joint Commission’s 2009 National Patient Safety Goals of medication reconciliation and appropriate anticoagulant management, this creates a perfect opportunity/forum for HDS-focused education. Future research should be aimed at “bridging the gap” through the development and implementation of both physician-focused and patient-focused educational tools.
Manuscript References


## Warfarin/HDS Interaction Table

<table>
<thead>
<tr>
<th>Supplement</th>
<th>Recommendation for Management</th>
<th>Warfarin Interaction</th>
<th>Platelet Interaction</th>
<th>Mechanism</th>
<th>Patient Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CAM therapies that may increase the risk of bleeding</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chondroitin sulfate (2-4)</td>
<td>!</td>
<td>+</td>
<td></td>
<td>Chondroitin is a small component of a heparinoid and might have weak anticoagulant activity</td>
<td></td>
</tr>
<tr>
<td>Cod liver oil-Essential Fatty Acids (5-9)</td>
<td>⇢</td>
<td></td>
<td></td>
<td>Cod liver oil contains omega-3 fatty acids, which may interfere with the ??????</td>
<td>Avoid drinking in large quantities</td>
</tr>
<tr>
<td>Cranberry (10-22)</td>
<td>!</td>
<td>+</td>
<td></td>
<td>Unknown mechanism: One proposed mechanism is that flavanoids in cranberry may interfere with the P450 2C9 metabolism of warfarin, thus prolonging its effects. Another hypothesis is that cranberry may increase the sensitivity of clotting factors to the effects of warfarin</td>
<td>-Have INR checked more frequently with chronic consumption</td>
</tr>
<tr>
<td>Evening primrose oil (31)</td>
<td>!</td>
<td>+</td>
<td></td>
<td>Primrose oil contains gamma-linolenic acid which has been show to inhibit thromboxane B2 production and increase prostacyclin production</td>
<td></td>
</tr>
<tr>
<td>Fish oil-Essential Fatty Acids (35,36)</td>
<td>⇢</td>
<td>+</td>
<td></td>
<td>Some research shows that the omega-3 component of fish oil may suppress thromboxane A2 synthesis. Conflicting research suggests that fish oil does not have an additive effect with aspirin</td>
<td>Data does suggest that 3-6g/day does not affect INR</td>
</tr>
<tr>
<td>Garlic (37-45)</td>
<td>Ø</td>
<td>+</td>
<td></td>
<td>Garlic has been shown to increase fibrinolytic</td>
<td>-Not all garlic products contain the constituents that possess</td>
</tr>
<tr>
<td>Supplement</td>
<td>Recommendation for Management</td>
<td>Warfarin Interaction</td>
<td>Platelet Interaction</td>
<td>Mechanism</td>
<td>Patient Information</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>--------------------------------</td>
<td>----------------------</td>
<td>----------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>activity, and may inhibit platelet aggregation by reducing thromboxane B2</td>
<td>“antiplatelet properties” - Garlic supplements should be stopped 10 days prior to surgery - Ingestion of normal amounts of dietary garlic should not affect bleeding times</td>
</tr>
<tr>
<td>Garlic (34,46-51)</td>
<td></td>
<td></td>
<td></td>
<td>“antiplatelet properties”</td>
<td>- Garlic supplements should be stopped 10 days prior to surgery - Ingestion of normal amounts of dietary garlic should not affect bleeding times</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mixed results in studies: one suggests a significant inhibition of platelet aggregation, where two others showed no affect on platelet function</td>
<td>- Caution with intake exceeding 4 grams of dried or 15 grams of raw ginger daily</td>
</tr>
<tr>
<td>Ginkgo biloba (49, 52-56)</td>
<td>Ø</td>
<td>+</td>
<td>+</td>
<td>Probable cytochrome P450 2C9 inhibition by ginkgo. Also, ginkgo is thought to displace platelet activating factor (PAF), inhibiting PAF-induced platelet aggregation</td>
<td></td>
</tr>
<tr>
<td>Glucosamine (2-4)</td>
<td>!</td>
<td></td>
<td>+</td>
<td>May have antiplatelet activity</td>
<td></td>
</tr>
<tr>
<td>Melatonin (62)</td>
<td>!</td>
<td></td>
<td></td>
<td>Unknown mechanism</td>
<td></td>
</tr>
<tr>
<td>Saw palmetto (63, 64)</td>
<td>!</td>
<td></td>
<td>+</td>
<td>Saw palmetto may inhibit cyclooxygenase, leading to increased risk of bleed</td>
<td></td>
</tr>
<tr>
<td>CAM therapies that may decrease the effects of warfarin</td>
<td></td>
<td></td>
<td></td>
<td>May inhibit platelet aggregation</td>
<td></td>
</tr>
<tr>
<td>Coenzyme Q10 (72-74)</td>
<td></td>
<td></td>
<td></td>
<td>May inhibit platelet aggregation</td>
<td></td>
</tr>
<tr>
<td>Ginseng (American) (76-78)</td>
<td>Ø</td>
<td></td>
<td>+</td>
<td>May inhibit platelet aggregation</td>
<td></td>
</tr>
<tr>
<td>Ginseng</td>
<td>Ø</td>
<td></td>
<td>+</td>
<td>May inhibit platelet aggregation</td>
<td></td>
</tr>
<tr>
<td>Supplement</td>
<td>Recommendation for Management</td>
<td>Warfarin Interaction</td>
<td>Platelet Interaction</td>
<td>Mechanism</td>
<td>Patient Information</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------------------</td>
<td>----------------------</td>
<td>----------------------</td>
<td>-----------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Soy (79)</td>
<td>☞</td>
<td>+</td>
<td></td>
<td>Soy isoflavones may alter warfarin drug absorption, metabolism or biliary excretion. They may also have antiplatelet effect. St. John’s wort is a cytochrome P450 enzyme inducer (CYP2C9, CYP1A2, CYP3A4)</td>
<td></td>
</tr>
<tr>
<td>St. John’s wort</td>
<td>☒</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table References:


35.


Appendix

Research Poster

**Introduction**

Nearly 20% of Americans use herbal and nonherbal supplements (HDS) which are often not disclosed to their care provider. Significant patient harm may occur when HDS are taken in conjunction with warfarin; however, the extent of risk with a rapidly evolving and increasing HDS industry is unknown.

**Methods**

The top 20 herbal and 20 nonherbal supplements used by Americans using 2008 sales data were reviewed for their potential to interact with warfarin using the Natural Medicines Comprehensive Database, AHFSDives (Micromedex) and Natural Standard databases. Search terms included common herbal names, warfarin, and anticoagulants, and drug-drug interactions. Databases were searched for relevant case reports and clinical trials which documented an herbal/supplement – drug interaction with reported changes in INR, bleed:thromboembolic events.

**Significant interactions with the most commonly used herbal and nonherbal supplements impact warfarin safety and efficacy**

Brittany Sagers, Undergraduate Researcher

Megan Bunch, Mentor

Nedra Christensen, Mentor

Jennifer Strubecker, Mentor

T. Jared Bunch, Mentor

**Results**

Of the 49 most commonly used HDS, more than half demonstrate an indirect or direct drug interaction with warfarin. Of the top 10 most commonly used, 90% have been reported to interact with warfarin. Overall, 14/49 (35%) were associated with a clinically significant change in INR. Specifically, 9/14 (64%) were found to potentiate a bleeding risk and 5/14 (36%) were found to decrease the effectiveness of warfarin.

**Conclusions**

Warfarin safety can be compromised by HDS use. These data demonstrate the widespread risk that warfarin-treated patients are exposed to when self-medicating with HDS and suggest medical providers must be proactive in discussing the risks of HDS-warfarin interactions with their patients.
Acknowledgments

Thank you to the Utah State University Undergraduate Research Office, Honors program and Dietetic program, and Intermountain Medical Center.
Author Biography

Brittany Jean Sagers was born in Salt Lake City, Utah. She was raised in Grantsville, Utah and graduated from Grantsville High School in 2005. She then attended Snow College in Ephraim, Utah as an Academic Excellence Scholar and graduated Magna Cum Laude with her Associate of Science degree in the spring of 2007. Brittany then transferred to Utah State University as a Dean’s Scholar to pursue her education in dietetics. She will graduate with her Bachelor of Science degree in Nutrition, Dietetics and Food Sciences with an emphasis in Dietetics in the spring of 2010.

During her career at Utah State, Brittany was a member of the Golden Key International Honor Society, the USU Honors Program and the USU Dietetics Club, as well as a student member of USU’s Undergraduate Research Advisory Board, representing the College of Agriculture for the 2009-2010 academic year.

Her future plans are to complete a dietetic internship through Utah State University in 2010-2011. After becoming a Registered Dietitian she is planning on achieving a Master of Dietetic Administration from Utah State University.